goserelin


Also found in: Dictionary, Wikipedia.
Related to goserelin: Leuprolide, tamoxifen, goserelin acetate, Zoladex

goserelin

 [go´sĕ-rel″in]
a synthetic gonadotropin-releasing hormone; upon administration it initially stimulates release of follicle-stimulating hormone and luteinizing hormone and on prolonged administration later suppresses them. It is used as the acetate salt to treat breast and prostate carcinomas and endometriosis and to thin the endometrium prior to endometrial ablation; administered by subcutaneous implant.

gos·er·e·lin

(gos'ĕr-ĕ-lin),
A synthetic decapeptide agonist analogue of LHRH (GnRH). It inhibits pituitary gonadotropin secretion and is used to treat prostate cancer, breast cancer, endometriosis, and for prethinning the endometrium before endometrial ablation or resection.

goserelin

/go·se·rel·in/ (go´sĕ-rel″in) a synthetic gonadotropin-releasing hormone; on prolonged administration it suppresses release of gonadotropins and is used as the acetate salt to treat breast and prostate carcinomas and endometriosis and to thin the endometrium prior to endometrial ablation.

goserelin

(gō′sə-rĕl′ĭn)
n.
A synthetic peptide analog of gonadotropin-releasing hormone used to treat prostate cancer, endometriosis, and advanced breast cancer.

gos·er·e·lin

(gō'sĕr-el'in)
A synthetic decapeptide agonist analogue of the luteinizing hormone-releasing hormone (GnRH); it inhibits pituitary gonadotropin secretion and is used in the treatment of prostate cancer, breast cancer, endometriosis, and for thinning the endometrium before endometrial ablation or resection.

goserelin

A gonadotrophin-releasing hormone used as a drug to treat ENDOMETRIOSIS, uterine FIBROIDS, MENORRHAGIA and cancer. A brand name is Zoladex.
References in periodicals archive ?
At 2 years, 22% of women receiving standard neoadjuvant or adjuvant chemotherapy alone and 8% of those receiving chemotherapy plus goserelin (Zoladex) experienced ovarian failure, defined as amenorrhea for the prior 6 months and follicle-stimulating hormone (FSH) in the postmenopausal range.
They examined a wide spectrum of testosterone levels, and the adverse effects of different levels, by temporarily suppressing the normal endogenous gonadal steroids of healthy men aged 20-50 years using subcutaneous goserelin.
Surprisingly, doctors also saw better survival among women given goserelin.
Findings of the study show that those who received AstraZeneca PLC's drug goserelin along with chemotherapy were 64 percent less likely to develop premature menopause than women who had chemotherapy alone and go on to have successful pregnancies.
During 3 years of ovarian suppression with goserelin (3.
Dalteparin, darbepoetin, dasatinib, dexamethasone + neomycin sulphate + polymyxin B sulfate, epoetin beta, epoetin theta, epoetin zeta, erlotinib, estradiol + cyproterone, etoricoxib, everolimus, follitropin beta, formoterol + beclomethasone, fusidic + betamethasone, fusidic + hydrocortisone , goserelin, hydromorphone hydrochloride, ketorolac, levothyroxine + liothyronine, Linezolid, nadroparin, paliperidone palmitate, pazopanib, pegfilgrastim, piribedil, progesterone, prothipendyl, Reviparin, risperidone, sildenafil, sumatriptan, tinzaparin, tobramycin, tobramycin + dexamethasone, voriconazole.
Of those who did have a relapse, 261 received goserelin compared with 330 who did not - a statistically significant 5 per cent difference which could translate into thousands of saved lives.
Hormone therapies like Tamoxifen and Goserelin tend to be viewed as a gentler option for patients - but the report today revealed that up to 99 per cent of women suffered side-effects.
Hormonal therapies, such as tamoxifen and goserelin, are seen as a gentler option for breast cancer patients.
Additional analysis of the findings showed that 8% of the men treated with goserelin and bicalutamide had a QT-interval prolongation of more than 60 msec.
Bone loss was significantly more severe in patients receiving combination therapy with goserelin and the aromatase inhibitor anastrozole (mean -16%) than in patients receiving goserelin with tamoxifen (mean -8%).
LONDON, November 16 /PRNewswire/ -- New research published today in the European Journal of Cancer (EJC) (1) indicates that an overwhelming 78 per cent of healthy premenopausal women would prefer goserelin ('Zoladex (TM)') therapy to chemotherapy if they were to develop oestrogen-receptor positive (ER+) early breast cancer, because of its superior side effect profile.